Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Other Accumulated Expenses: 2021-2025

Historic Other Accumulated Expenses for Roivant Sciences (ROIV) over the last 5 years, with Sep 2025 value amounting to $1.5 million.

  • Roivant Sciences' Other Accumulated Expenses fell 97.38% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 97.38%. This contributed to the annual value of $1.6 million for FY2025, which is 95.80% down from last year.
  • Roivant Sciences' Other Accumulated Expenses amounted to $1.5 million in Q3 2025, which was down 97.04% from $49.8 million recorded in Q2 2025.
  • In the past 5 years, Roivant Sciences' Other Accumulated Expenses registered a high of $76.3 million during Q1 2023, and its lowest value of $1.5 million during Q3 2025.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $49.8 million (2025), whereas its average is $45.1 million.
  • In the last 5 years, Roivant Sciences' Other Accumulated Expenses surged by 1,940.32% in 2022 and then slumped by 97.38% in 2025.
  • Over the past 5 years, Roivant Sciences' Other Accumulated Expenses (Quarterly) stood at $12.4 million in 2021, then surged by 352.97% to $56.3 million in 2022, then declined by 22.55% to $43.6 million in 2023, then grew by 22.55% to $53.5 million in 2024, then plummeted by 97.38% to $1.5 million in 2025.
  • Its Other Accumulated Expenses was $1.5 million in Q3 2025, compared to $49.8 million in Q2 2025 and $1.6 million in Q1 2025.